Tempus revenue growth, turns EBITDA positive, raises 2026 guidance, 510(k) oks

 

Tempus AI posts 23% revenue growth, turns EBITDA positive, raises 2026 guidance, wins FDA 510(k) clearances for ECG-PH and ECG-MR

• Q3 revenue $411.5m, +23% YoY, beat estimates, driven by oncology diagnostics and data and applications strength.
• Q3 EPS $0.07, +164% YoY, with adjusted EBITDA $25.6m marking first meaningful profitability despite continued growth investments.
• Diagnostics revenue $303.5m, +20% YoY; oncology +28% with 32% unit growth, accelerating.
• Data and applications revenue $108.1m, +33% YoY; Insights segment grew 29%.
• Raised 2026 revenue guidance to $1.60–$1.605b and reiterated outlook for ~ $65m adjusted EBITDA.
• Signed BMS/Pathos deals adding expected $192.5m data revenue over ~5 years.
• Personalis MRD acquisition received regulatory clearance, with shareholder vote on the transaction scheduled for November 30.
• Personalis MRD acquisition expected to pressure margins near term until reimbursement improves around the mid‑2027 timeframe.
• Hereditary testing stabilizing after tough comps; units back to low‑double‑digit growth recently.
• Oncology ASP tailwinds from FDA approvals and ADLT pricing expected to lift 2027 revenue.
• Key risks: MRD economics and reimbursement, Personalis losses and integration, margin pressure before expected 2027 inflection while sustaining 25% growth.
• Strong quarter, driven by robust oncology growth, surging data business, and operating leverage to positive EBITDA.

https://finviz.com/stock?t=TEM&p=d